FCE
ALXN

Fiera Capital (Europe)’s Alexion Pharmaceuticals ALXN Stock Holding History

Fiera Capital (Europe)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,644
Closed -$191K – 45
2016
Q2 		$191K Buy
+1,644
New +$233K 0.15% 34

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fiera Capital (Europe)'s ALXN Position: Q3 2016 in Review

Fiera Capital (Europe) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 1,644 shares — an estimated $191K sold.

Fiera Capital (Europe) first reported a position in ALXN in Q2 2016 and held it in 1 quarter. The position peaked at $191K in Q2 2016. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Fiera Capital (Europe) reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Fiera Capital (Europe) sold 1,644 Alexion Pharmaceuticals shares in Q3 2016, an estimated $191K.
  • Fiera Capital (Europe) first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Fiera Capital (Europe)'s Alexion Pharmaceuticals position peaked at $191K in Q2 2016.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Fiera Capital (Europe)'s 13F filing for Q3 2016, filed 10 Nov 2016.